Email this article Effect of Stimforte in combination with Virazole on infection induced by hepatitis C virus in mice
- Issue: Vol 54, No 3 (2009)
- Pages: 42-44
- Section: Articles
- Submitted: 09.06.2023
- Published: 15.06.2009
- URL: https://virusjour.crie.ru/jour/article/view/11921
- ID: 11921
Cite item
Full Text
Abstract
Twenty-four hours after intramuscular injection of Stimforte in a dose of 25 mg in mice weighing 18-20 g, chronically infected with hepatitis C virus (HCV), viral infection was shown to be at the most suppressed viral replication, as suggested by the data of the infectious and antigenic activities of HCV. Following 72 hours of its administration, the quantity of viral antigen and the infectious activity restored.
Readministration of the agent considerably suppressed HCV replication. When given in a dose of 12.5 mg/kg, the agent reduced HCV titers by 2.0-2.5 log10 TCID50; when used in a dose of 25 mg/kg, it diminished the infectious activity of HCV by 3.2 log. The similar data were obtained in the study of the antigenic activity of HCV in infected animals. The effect of Virazole in combination with Stimforte in reducing the replication of infectious HCV and the accumulation of antigens in HCV-infected mice was additive or synergic, suggesting that it is expedient to use them concurrently.
Readministration of the agent considerably suppressed HCV replication. When given in a dose of 12.5 mg/kg, the agent reduced HCV titers by 2.0-2.5 log10 TCID50; when used in a dose of 25 mg/kg, it diminished the infectious activity of HCV by 3.2 log. The similar data were obtained in the study of the antigenic activity of HCV in infected animals. The effect of Virazole in combination with Stimforte in reducing the replication of infectious HCV and the accumulation of antigens in HCV-infected mice was additive or synergic, suggesting that it is expedient to use them concurrently.
Keywords
References
- Дерябин П. Г., Вязов С. О., Исаева Е. И. и др. Персистенция вируса гепатита С в культурах клеток головного мозга мышей сосунков // Вопр. вирусол. - 1997. - № 6. - С. 254-258.
- Дерябин П. Г., Львов Д. К. Высокопродуктивный вариант вируса гепатита С. Выделение, характеристика, идентификация // Докл. РАН. - 1998. - Т. 358, № 5. - С. 688-691.
- Львов Д. К. Вирусные гепатиты // Вопр. вирусол. - 2002. - Т. 47, № 6. - С. 44-46.
- Carlsson T., Reichard O., Norkrans G. et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response // J. Viral Hepatit. - 2005. - Vol. 12, N 5. - P. 473-480.
- Carnicer F., Zapater P., Gutiйrez A. et al. Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin // Rev. Esp. Enferm. Dis. - 2005. - Vol. 97, N 5. - P. 299-305.
- Clarke D. H., Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses // Am. J. Trop. Med. Hyg. - 1958. - Vol. 7, N 5. - P. 561-573.
- Heathcote E. J. Antiviral therapy: chronic hepatitis C // J. Viral Hepatit. - 2007. - Vol. 14, N 1. - Suppl. - P. 82-88.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).